- Home
- SSSS vs BMEA Comparison
SSSS vs BMEA Comparison
Compare SSSS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- BMEA
- Stock Information
- Founded
- SSSS 2010
- BMEA 2017
- Country
- SSSS United States
- BMEA United States
- Employees
- SSSS N/A
- BMEA N/A
- Industry
- SSSS Finance: Consumer Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- BMEA Health Care
- Exchange
- SSSS Nasdaq
- BMEA Nasdaq
- Market Cap
- SSSS 137.0M
- BMEA 125.4M
- IPO Year
- SSSS N/A
- BMEA 2021
- Fundamental
- Price
- SSSS $5.01
- BMEA $2.13
- Analyst Decision
- SSSS Buy
- BMEA Buy
- Analyst Count
- SSSS 2
- BMEA 13
- Target Price
- SSSS $8.00
- BMEA $27.92
- AVG Volume (30 Days)
- SSSS 229.8K
- BMEA 656.7K
- Earning Date
- SSSS 03-11-2025
- BMEA 05-01-2025
- Dividend Yield
- SSSS N/A
- BMEA N/A
- EPS Growth
- SSSS N/A
- BMEA N/A
- EPS
- SSSS N/A
- BMEA N/A
- Revenue
- SSSS $4,673,427.00
- BMEA N/A
- Revenue This Year
- SSSS N/A
- BMEA $191.34
- Revenue Next Year
- SSSS N/A
- BMEA N/A
- P/E Ratio
- SSSS N/A
- BMEA N/A
- Revenue Growth
- SSSS N/A
- BMEA N/A
- 52 Week Low
- SSSS $3.52
- BMEA $2.10
- 52 Week High
- SSSS $6.83
- BMEA $16.29
- Technical
- Relative Strength Index (RSI)
- SSSS 35.42
- BMEA 28.47
- Support Level
- SSSS $5.65
- BMEA $2.27
- Resistance Level
- SSSS $5.99
- BMEA $3.08
- Average True Range (ATR)
- SSSS 0.30
- BMEA 0.23
- MACD
- SSSS -0.08
- BMEA 0.00
- Stochastic Oscillator
- SSSS 9.26
- BMEA 2.95
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.